At a glance
- Harminder S Dua,
- Arun D Singh, Editors-in-Chief
Mass treatment of trachoma with azithromycin eye drops
Huguet et al undertook a campaign to treat the entire population of Kolofata Health District, Cameroon with azithromycin 1.5% eye drops as part of a trachoma elimination programme. One drop in each eye, twice a day for three consecutive days (six doses) was administered to 96.6% of the total population (115 274). Epidemiological studies were conducted just prior to and one year after treatment on a representative sample of children (aged 1–10 years) to measure the effectiveness of treatment. The authors observed 80% reduction in the prevalence of active forms of trachoma (from 31.5% to 6.3 %). Moreover, the treatment was tolerated well.
See page 157
Bevacizumab and reduced light dose PDT in AMD: the VIA study
Potter et al conducted a randomised, double-masked, controlled clinical trial (36 patients) to determine if light-dose PDT combined with bevacizumab will decrease the number of bevacizumab treatments required over 6 months in neovascular AMD. Patients received intravitreal bevacizumab plus PDT using a light dose …
